Ceramide composition and method of use
View Patent ↗A method for treating and preventing diseases associated with neutrophil infiltration, particularly ocular diseases, is provided, which method comprises administering to a subject in need thereof an effective amount of ceramide or a derivative thereof. Also provided is a composition for treating diseases associated with neutrophil infiltration, the composition comprising ceramide or a derivative thereof.
1. A method for treating ocular tissue injury or diseases comprising administering to a subject in need thereof a composition comprising a C 6 -ceramide containing nanoliposome, wherein the ocular disease is a disease associated with neutrophil infiltration in a cell.
2. The method of claim 1 wherein the ceramide thereof is administered at a dosage of about 1 nanogram to about 100 micrograms per day.
3. The method of claim 1 wherein the composition inhibits mitogen-activated protein (MAP) kinases signaling.
4. The method of claim 3 wherein the MAP kinases is at least one of JNK and p38.
5. The method of claim 1 wherein the ceramide downregulates chemotatic mediators that recruit neutrophils to the site of tissue injury via Toll-like and cytokine receptors.
6. The method of claim 1 wherein the ocular disease is a disease of the anterior eye.
7. The method of claim 6 wherein the ocular disease is at least one of keratitis, endophthalmitis, uveitis, conjunctivitis, blepharitis, contact lens-induced peripheral ulcer and corneal dystrophy.
8. The method of claim 1 wherein the ocular disease is a disease of the posterior eye.
9. The method of claim 8 wherein the ocular disease is at least one of retinitis pigmentosa, diabetic retinopathy, macular degeneration and ocular toxoplasmosis.
10. The method of claim 1 wherein the ocular disease is caused by refractive or laser surgery.
11. A method for preventing ocular diseases associated with neutrophil infiltration in a cell comprising administering to a subject in need thereof a composition comprising a C 6 -ceramide containing nanoliposome.
12. The method of claim 11 wherein the ocular disease is a disease of the anterior eye.
13. The method of claim 12 wherein the ocular disease is at least one of keratitis, endophthalmitis, uveitis, conjunctivitis, blepharitis, contact lens-induced peripheral ulcer and corneal dystrophy.
14. The method of claim 11 wherein the ocular disease is a disease of the posterior eye.
15. The method of claim 14 wherein the ocular disease is at least one of retinitis pigmentosa, diabetic retinopathy, macular degeneration and ocular toxoplasmosis.